Abstract: Methods of treatment for a subject having breast cancer, and who has received neoadjuvant chemotherapy (NAC), involve detecting expression levels of genes in a first signature including: PDCD1, NKG7, LAG3, GZMH, GZMB, GNLY, FGFBP2, and HLA-DRB5, and administering additional chemotherapy prior to surgery, or administering additional chemotherapy after surgery when the subject is identified as having a likelihood of residual disease (RD); or proceeding with surgery without administering additional chemotherapy when the subject is identified has having a likelihood of pathological complete response (pCR).

Abstract: Provided herein are methods for treating and preventing PD-1-mediated resistant cancers.

Abstract: A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.

Abstract: The presently-disclosed subject matter relates to methods and systems for examining tumor samples, methods and systems for identifying subjects who are likely responders to treatment, and methods for treating cancer. In some embodiments, the presently-disclosed subject matter relates to determining expression of a major histocompatibility complex-II (MHC-II) molecule on a cell from a tumor sample, and further involving determining presence of tumor-infiltrating T cells in the tumor sample, determining the presence of tumor-infiltrating lymphocytes in the tumor sample, detecting chemokine expression in the tumor sample, and/or detecting TP53 mutations in the tumor sample. In some embodiments, the method involves treatment with an immunotherapeutic agent either alone or in combination with an MDM2 antagonist or an MEK inhibitor.

Abstract: A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.

Abstract: The presently-disclosed subject matter relates to biomarker profiling of samples obtained from carcinoma subjects who are candidates for treatment with a therapeutic EGFR inhibitor. More specifically, the presently-disclosed subject matter provides methods of biomarker profiling which allow one skilled in the art to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.